041910.KQ EstechPharma Co. Ltd
- Market cap
- KRW 73.7B
- P/E
- -
- P/B
- 0.50x
- ROE
- 14.1%
- Dividend yield
- -
- Fundamental score
- 2.1/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 041910.KQ undervalued?
Graham numberThe Graham number of EstechPharma Co. Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
EstechPharma Co. Ltd fundamental analysis
11 of 22 checks passedROE 1/2
Moderate return on equity (14.1%), between 10% and 20%.
ROA 1/1
Return on assets (10.6%) is above the industry median (3.4%).
Profit Consistency 1/2
Profitable for 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 1/1
Last year's EPS growth (56.1%) is above the 5-year average (-13.1% a year).
Earnings Growth vs Industry 1/1
Last year's EPS growth (56.1%) is above the industry median (6.6%).
Revenue Growth 0/2
Revenue shrank 3.6% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (24.7%), 40% or less.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Debt Coverage 1/1
Operating cash flow covers 20% of total debt.
Interest Coverage 1/1
EBIT is 999.1x against interest expense, well covered.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 1/1
Price to book (0.5x) is below the industry median (0.8x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
EstechPharma Co. Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About EstechPharma Co. Ltd
EstechPharma Co., Ltd. manufactures and sells pharmaceuticals products. It also offers raw materials, such as RBM and PLK. The company was formerly known as Estech Chemical and changed its name to EstechPharma Co., Ltd. in January 2001. EstechPharma Co., Ltd. was founded in 1996 and is headquartered in Hwaseong-si, South Korea.
Full company profileEstechPharma Co. Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
EstechPharma Co. Ltd annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 43.4B | 38.2B | 40.3B | 46.5B | 61.3B | 60.4B | 62.0B | 64.2B | 59.6B | 55.5B | 56.8B |
| Gross Profit | 11.7B | 11.1B | 9.85B | 13.0B | 17.4B | 13.8B | 12.7B | 14.3B | 11.3B | 12.3B | 14.1B |
| Operating Income | 3.96B | 2.87B | 1.52B | 3.79B | 7.00B | 4.21B | 3.16B | 5.34B | 235M | 3.19B | 2.77B |
| EBITDA | - | - | - | - | - | - | -5.84B | 6.83B | 6.60B | 9.95B | 28.8B |
| Net Income | 4.15B | 2.73B | 6.59B | 15.2B | 11.0B | 6.87B | -6.36B | 3.82B | 3.95B | 6.16B | 20.8B |
| EPS | 368 | 236 | 564 | 1,304 | 938 | 589 | -545 | 327 | 297 | 464 | 1,566 |
| Balance Sheet | |||||||||||
| Total Assets | 97.5B | 95.0B | 98.3B | 116B | 123B | 134B | 124B | 122B | 134B | 196B | 197B |
| Total Liabilities | 20.0B | 12.6B | 9.09B | 13.7B | 11.8B | 11.1B | 8.23B | 6.27B | 5.87B | 60.0B | 48.8B |
| Shareholders' Equity | 77.4B | 82.4B | 89.3B | 103B | 111B | 123B | 116B | 116B | 129B | 136B | 148B |
| Cash & Short-term Investments | 20.5B | 21.5B | 23.9B | 40.3B | 41.3B | 51.0B | 30.6B | 27.5B | 46.7B | 26.8B | 34.5B |
| Total Debt | 13.0B | - | - | 368M | 163M | - | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 8.19B | 6.99B | 7.25B | 4.29B | 4.71B | 603M | -1.65B | 4.79B | 7.93B | 8.83B | 10.3B |
| Capital Expenditure | 2.09B | 692M | 466M | 1.13B | 2.20B | 2.00B | 1.51B | 1.02B | 5.45B | 555M | 602M |
| Free Cash Flow | - | - | - | -396M | 2.42B | -1.45B | -3.16B | 3.77B | 2.48B | 8.28B | 9.66B |
| Ratios | |||||||||||
| ROE | 5.4% | 3.3% | 7.4% | 14.8% | 9.8% | 5.6% | -5.5% | 3.3% | 3.1% | 4.5% | 14.1% |
| ROA | 4.3% | 2.9% | 6.7% | 13.1% | 8.9% | 5.1% | -5.1% | 3.1% | 2.9% | 3.1% | 10.6% |
| Net Profit Margin | 9.6% | 7.1% | 16.3% | 32.8% | 17.9% | 11.4% | -10.3% | 6.0% | 6.6% | 11.1% | 36.6% |
| Debt to Equity | 0.17x | - | - | 0.00x | 0.00x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
EstechPharma Co. Ltd dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | KRW 1.17B | 88 | 29.6% |
| 2023 | KRW 1.17B | 100 | 30.5% |
| 2022 | KRW 1.17B | 100 | - |
| 2021 | KRW 1.17B | 100 | 17.0% |
| 2020 | KRW 1.17B | 100 | 10.7% |
| 2019 | KRW 584M | 50 | 3.8% |
| 2018 | KRW 578M | 49 | 8.8% |
| 2017 | KRW 564M | 49 | 20.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 98163:89239 on May 9, 2005.
Who owns EstechPharma Co. Ltd
- Insiders 24.93%
- Institutions 1.17%
- Public & others 73.90%
- Shares outstanding 11.7M
- Free float 8.71M
EstechPharma Co. Ltd company profile
- Company name
- EstechPharma Co. Ltd
- Ticker
- 041910.KQ
- ISIN
- KR7041910001
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 159
- Fiscal year end
- December
- Address
- 25, Balan-gongdan-ro, Hwaseong-si, South Korea
- Phone
- 82 3 1831 4800
- Website
- estechpharma.com
About EstechPharma Co. Ltd
EstechPharma Co., Ltd. manufactures and sells pharmaceuticals products. It also offers raw materials, such as RBM and PLK. The company was formerly known as Estech Chemical and changed its name to EstechPharma Co., Ltd. in January 2001. EstechPharma Co., Ltd. was founded in 1996 and is headquartered in Hwaseong-si, South Korea.
EstechPharma Co. Ltd management
4- Mr. Jae-Chul KimChief Exec. Officer and Pres · born 1960
- Mr. Sung-Kil KangManaging Director and Director · born 1966
- Gyeong Jae SeoManaging Director and Director · born 1965
- Sung-Dae ParkDirector of R&D · born 1958